Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Assess tax efficiency between retirement strategies focusing on Total World exposure to boost after-tax returns.
28,221 articlesLilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Microsoft is shifting toward building its own AI backbone. This article explores what that means for investors, how i...
A biotech stock winner has surged 72%, yet a disciplined stake trim suggests a cautious pause. Here’s how to read the...
Looking to ride a big move in a small-cap space? Learn how to spot a small-cap growth stock before it hits its next e...
When a famous entertainer pulls out of an event over misrepresentation, budgets, sponsors, and fans all feel the ripp...
As EV demand grows and policy shifts unfold, investors are sizing up 2026. This guide breaks down the chances of a re...
A bold public project turns a mountain of documents into a temporary library in New York. This article breaks down th...
Could AI excitement be lifting prices beyond fundamentals? This guide flags three warning signs and offers actionable...
Seeking a stock with growth, resilience, and optionality? This article lays out three strong reasons to consider Lill...
A big new stake in Ryan Specialty Holdings hints at growing confidence from a niche investor. This article breaks dow...
Celebrity headlines can spill into everyday money decisions. This piece breaks down budgeting for weddings, media dra...
A close look at gwyneth paltrow’s latest capsule-wardrobe moment reveals a budget-friendly shortcut that adds up over...